A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents With Autism Spectrum Disorders
Latest Information Update: 10 Feb 2023
At a glance
- Drugs Arbaclofen (Primary)
- Indications Pervasive child development disorders
- Focus Therapeutic Use
- Acronyms AIMS2-CT1
- 07 Feb 2023 Status changed from recruiting to completed.
- 10 Aug 2022 Planned End Date changed from 31 Aug 2022 to 31 Dec 2022.
- 10 Aug 2022 Planned primary completion date changed from 31 Aug 2022 to 31 Dec 2022.